All In Biotech

NDA 209803 · Msd Sub Merck

Steglatro

Ertugliflozin · Oral

Novel

Last checked: Nov 20, 2026Latest source record: Jun 3, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Dec 19, 2017

Approved uses

2

Original approval plus efficacy supplements

Registered trials

43

14 Phase 3, 5 recruiting

FAERS reports

1,116

520 serious, 12 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 3, 2026.

STEGLATRO ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. STEGLATRO is a sodium glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use: Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. ( 1 ) Limitations of Use Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions (5.1) ] .

Mechanism: SGLT2 is the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. Ertugliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, ertugliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • STEGLATRO · ERTUGLIFLOZIN 5MG · TABLET, ORAL · Prescription · TE AB
  • STEGLATRO · ERTUGLIFLOZIN 15MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Ertugliflozin" as an intervention, any sponsor and status, largest first.

All 43 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea91
  • product dose omission issue71
  • urinary tract infection66
  • vomiting65
  • fungal infection58
  • no adverse event56
  • diabetic ketoacidosis54
  • blood glucose increased51
  • dizziness49
  • diarrhoea47
  • drug ineffective41
  • product dose omission29

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20131
20172
2018132
2019280
202095
202181
202296
2023112
2024116
2025125
202676

Recalls

1 FDA enforcement reports for this application.

  • Mar 15, 2021 · Class II · Terminated

    CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Steglatro (Ertugliflozin Pidolate)

2024 spending

$16.5M

Beneficiaries

11,118

38,152 claims

Per beneficiary

$1,487

$11.45 per unit

View as table
YearSpending
2020$11,370,498
2021$15,018,152
2022$17,276,294
2023$18,207,799
2024$16,530,191

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 120 on PubMed

Sponsor: Merck & Co.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.